Medium ACT Target for Coronary Artery Disease

"High ACT Target is commonly used for medical device treatment, however its efficacy in other contexts has also been observed. It can be taken to address sprains and heart conditions such as unstable angina pectoris or atrial fibrillation."

"As of today, the clinical trial is actively seeking patients. Its initial posting was on February 8th 2019 and it underwent its most recent edit on 14th February 2022 according to the data available from clinicialtrials.gov."

"Affirmative. According to clinicaltrials.gov, this experiment was initially posted back on February 8th 2019 and has been recently updated in February 14th 2022; it is currently looking for 546 patients conducted at a single site."

"With an optimistic assessment based on the Phase 2 classification, High ACT Target can be deemed moderately safe with a score of 2. It should be noted that while safety is supported by data, efficacy has yet to be clinically confirmed."

"Initiated in 2006, High ACT Target has been subject to growing scrutiny and clinical trials since. The first such study was sponsored by Ash Access Technology and involved 415 participants, resulting in the drug's Phase 3 approval. Currently, 36 separate studies are underway across 197 cities spanning 21 countries."

"At the present time, there are 12 Phase 3 experiments and 36 active trials assessing High ACT Target. Of those studies, 367 sites have been chosen to host them; particularly in Sherbrooke, Quebec."